Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study.
Phase of Trial: Phase II
Latest Information Update: 13 Apr 2018
At a glance
- Drugs Docetaxel (Primary) ; Pembrolizumab (Primary)
- Indications Salivary gland cancer; Thyroid cancer
- Focus Therapeutic Use
- Acronyms The iPRIME Study
- 09 Apr 2018 Status changed from not yet recruiting to recruiting.
- 06 Dec 2017 New trial record